Abstract Introduction Metastatic spine disease (MSD) occurs in up to 40% of cancer patients; advancements in treatment including systemic therapies, radiotherapy, and surgical decompression and stabilization have improved outcomes and extended survival. As a result, the long-term integrity of spine instrumentation is o...
Andrew A. Hardigan, F. Landriel, F. Cofano et al.· Neuro-Oncology Advances· 0 citations
Postoperative AE’s are extremely relevant to the care of patients with MSD and impact both HRQoL and survival and a multivariate analysis demonstrated that age, smoking status, ECOG performance, prior radiotherapy, presence of multiple metastases at other sites, and multiple spine metastases were significant risk facto...
Andrew A. Hardigan, G. B. Brodano, Christina Griffoni et al.· Neuro-Oncology Advances· 0 citations
Abstract Introduction Given the palliative nature of treatment for metastatic spine disease (MSD), measuring surgical outcomes in this population requires examining comprehensive outcome variables. We sought to achieve an international consensus in how to measure success in the MSD population. Methods The AO Spine Know...
Andrew A. Hardigan, R. de la Garza Ramos, Michael H. Weber et al.· Neuro-Oncology Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
